We are live on ! Find out more
AVA

Atlas Venture Advisors Portfolio holdings

AUM $122M
1-Year Est. Return 26.28%
This Fund
S&P 500
This Quarter Est. Return
-37.2%
1 Year Est. Return
-26.28%
3 Year Est. Return
-22.79%
5 Year Est. Return
-46.44%
10 Year Est. Return
AUM
$189M
AUM Growth
Cap. Flow
+$233M
Cap. Flow %
122.8%
Top 10 Hldgs %
100%
Holding
5
New
5
Increased
Reduced
Closed

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Technology 69.58%
2 Healthcare 29.71%
3 Communication Services 0.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CBLK
1
DELISTED
Carbon Black, Inc. Common Stock
CBLK
$132M 69.58%
+9,823,103
New +$161M
TBIO
2
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$29.4M 15.53%
+3,922,008
New +$28.7M
LRMR icon
3
Larimar Therapeutics
LRMR
$416M
$17.4M 9.16%
+292,184
New +$28.8M
VRDN icon
4
Viridian Therapeutics
VRDN
$2.13B
$9.52M 5.03%
+209,505
New +$12.1M
SNAP icon
5
Snap
SNAP
$7.32B
$1.35M 0.71%
+245,076
New +$1.59M

Similar funds

Atlas Venture Advisors's Q4 2018 Portfolio in Review

Q4 2018 is the first quarter with a 13F filing on record for Atlas Venture Advisors, which disclosed 5 positions worth $189M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Carbon Black, Inc. Common Stock: 9,823,103 shares worth $132M.

By sector, the portfolio is most concentrated in Technology at 70% of assets, followed by Healthcare and Communication Services.

  • Atlas Venture Advisors's largest Q4 2018 buy was Carbon Black, Inc. Common Stock: 9,823,103 shares worth $132M.
  • Atlas Venture Advisors's ten largest holdings make up 100% of its $189M portfolio in Q4 2018.
  • Atlas Venture Advisors disclosed 5 positions in Q4 2018, its first 13F filing on record.

Based on Atlas Venture Advisors's 13F filing for Q4 2018, filed 8 Feb 2019.